Category: Stent Wars
Seven-year results from Boston Scientific's MADIT-CRT trial show long-term benefits for some patients with mild heart failure.
Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific's (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology's annual meeting over the weekend.
Medtech titan Medtronic touts a relatively minor clinical trial win for the physical integrity of its Resolute drug-eluting stent in what is otherwise a tie with Boston Scientific's Promus Element device.
The U.S. Supreme Court denies stent pioneer Dr. Bruce Saffran's appeal of a $600 million patent infringement decision to Johnson & Johnson's Cordis stent-making arm.
Johnson & Johnson's (NYSE:JNJ) Cordis stent-making arm won the final round in a patent infringement battle with stent pioneer Dr. Bruce Saffran when the U.S. Supreme Court yesterday declined to hear Saffran's appeal.
The FDA grants pre-market approval to Boston Scientific's next-generation Promus Premier coronary stent.
Boston Scientific (NYSE:BSX) said the FDA granted pre-market approval for its next-generation coronary stent, the Promus Premier.
Natick, Mass.-based Boston Scientific said it plans an immediate release for the Promus Premier, a drug-eluting stent made of a platinum-chromium alloy coated with everolimus.
The U.S. Court of Appeals for the Federal Circuit declines to revisit its decision to uphold a lower court's decision to invalidate patents for drug-eluting coronary stent technology.
A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.
Boston Scientific agrees to pay an undisclosed amount to settle patent infringement cases against OrbusNeich in the U.S. and Europe over coronary stent technology.
Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.
Boston Scientific finishes enrolls the last of 1,684 patients in the Evolve II trial of its Synergy drug-eluting stent.
Boston Scientific (NYSE:BSX) said it finished enrolling 1,684 patients in a clinical trial of its next-generation Synergy drug-eluting stent, aiming to use the data to back regulatory nods in the U.S. and Canada.